Skip to main content
. 2021 Oct 30;22(21):11791. doi: 10.3390/ijms222111791

Figure 1.

Figure 1

Aβ levels (ELISA) in brain homogenates of hAPPsl×hQC mice after treatment with PQ912 (Varoglutamstat), a monoclonal pGlu-Aβ antibody (m6-Ab) or in combination for 16 weeks. Concentration of Aβ(x–42) (a,b) and pGlu3-Aβ(3–42) (c,d) in soluble (a,c) and insoluble (b,d) brain fractions of 12-months-old hAPPsl×hQC mice after 16 weeks of treatment. Dots represent individual levels. Bars and whiskers represent mean ±95% confidence interval (CI). ANOVA p-values are given on top of the graphs. Numbers above the bars represent adjusted p-values of Dunnett’s post-hoc comparison with the isotype control (*—p < 0.05, **—p < 0.01). There is a nominal decrease of total Aβ42 and pGlu3-Aβ42 by the single treatments. The effect of the combination is stronger compared to the single treatment and becomes significant for pGlu3-Aβ in both fractions and for Aβ42 in the TBS fraction.